ALEC / Alector (ALEC) Surpasses Q2 Earnings and Revenue Estimates

Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. more_horizontal

The average of price targets set by Wall Street analysts indicates a potential upside of 102% in Alector (ALEC). While the effectiveness of this highl more_horizontal

Alector (ALEC) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.81 per share. This compares t more_horizontal

Artificial intelligence technology is transforming many industries and creating new opportunities for businesses and consumers. But as an investor, ho more_horizontal

The consensus price target hints at an 86.4% upside potential for Alector (ALEC). While empirical research shows that this sought-after metric is hard more_horizontal

Alector (ALEC) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.5 more_horizontal

Alector, Inc. has a lot of cash for a small biotech, but it is also trading at cash. Alector, Inc. has a late-stage program in a CNS indication and ma more_horizontal

Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the s more_horizontal